Startups addressing diabetes, kidney disease, digestive disorders and metabolic conditions can pursue non-dilutive research funding through the National Institute of Diabetes and Digestive and Kidney Diseases Small Business Program. NIDDK participates in both the NIH SBIR and STTR programmes and

Bringing a new neurological therapy, brain device or biomarker to market often requires years of development before commercial investors are willing to take the risk. The National Institute of Neurological Disorders and Stroke Small Business Program provides non-dilutive SBIR and

Startups developing vaccines, diagnostics, therapeutics and other infectious-disease technologies can access substantial non-dilutive R&D funding through the National Institute of Allergy and Infectious Diseases. NIAID participates in the NIH SBIR and STTR programmes and supports commercial product development across infectious

Medical innovations addressing cardiovascular disease, respiratory conditions, blood disorders and sleep medicine can access substantial non-dilutive support through the National Heart, Lung, and Blood Institute Small Business Program. NHLBI participates in NIH’s SBIR and STTR programmes and supports businesses developing